Nandrolone decanoate
Nandrolone decanoate, injectable 19-nortestosterone ester
Written by Aaron CuhaReviewed Sep 2026
Also known as: Deca-Durabolin, Deca, 19-nortestosterone
Randomised trials in dialysis, in burns, and a 2025 meta-analysis in postmenopausal osteoporosis. The medical record is real and the drug was withdrawn in most markets anyway.
Overview
Nandrolone has the broadest medical trial record of any anabolic steroid besides testosterone itself, across three separate populations that share one feature: the body is losing tissue it cannot replace.
In dialysis patients, a randomised trial in JAMA found anabolic effects. In severe burns, a randomised trial found it safely countered catabolism, and that paper is explicitly framed as a potential new indication after the drug had been withdrawn. In postmenopausal osteoporosis, a 2025 systematic review and meta-analysis of randomised trials concluded it is a potential adjuvant option for selected women, particularly where muscle loss or refractory bone pain is present, under close clinical and laboratory monitoring, while calling for larger contemporary trials to define its role.
That last finding matters for a specific reader. Women losing both muscle and bone after menopause are among the least well served by current options, and this is a class with an evidence base that almost nobody puts in front of them.
Mechanism of action
19-nortestosterone, testosterone lacking the 19-carbon methyl group, esterified with decanoic acid for a long-acting oil depot. It binds the androgen receptor with high affinity and is a poor substrate for aromatase, so it produces relatively little oestradiol. Crucially it is reduced by 5-alpha-reductase to dihydronandrolone, which is a weaker androgen than the parent, the opposite of what happens with testosterone. That is why it is comparatively less androgenic in tissues rich in 5-alpha-reductase such as scalp and prostate, and it is also part of why it has distinct central effects, including a well-documented association with sexual dysfunction that patients often find surprising given it is an anabolic steroid.
Human evidence
Randomised evidence across three distinct wasting populations plus pooled evidence in postmenopausal osteoporosis. Unusually broad for an anabolic steroid, and concentrated in disease states rather than in healthy people.
- Randomised controlled trial in dialysis patients published in JAMA reporting anabolic effects.
- Randomised phase 2 dose-finding study in chronic kidney disease, so dose was investigated rather than assumed.
- Randomised controlled trial in burned patients reporting it safely counters catabolism.
- Systematic review and meta-analysis of randomised trials in postmenopausal osteoporosis, concluding it is a potential adjuvant in selected women with close monitoring.
- Sexual dysfunction is a recognised and somewhat counterintuitive effect, related to its poor aromatisation and to reduction into a weaker androgen.
- Withdrawn from the United States market despite that record, which is a regulatory and commercial fact rather than a finding about efficacy.
What this does not tell you: Much of this evidence is old, and the 2025 meta-analysis says so directly in calling for larger contemporary trials. The osteoporosis conclusion is explicitly about selected women under close monitoring rather than a general recommendation, and modern osteoporosis treatment has options that did not exist when most of these trials were run. Nothing here concerns healthy adults seeking muscle. And because the drug is withdrawn in the United States, material sold under its street name is unverified, so none of this evidence can be assumed to apply to it.
Reading the research record
The interesting thing about nandrolone is that its medical evidence is better than its regulatory status, and the two facts are not in conflict.
It has randomised trials in dialysis, chronic kidney disease and burns, plus pooled randomised evidence in postmenopausal osteoporosis. That is a real record. It was also withdrawn from the United States market, because a drug can be withdrawn for commercial reasons, because safer alternatives arrived, or because the indication it held is now treated differently, none of which is a finding that it does not work.
The postmenopausal osteoporosis evidence deserves particular attention because of who it concerns. Women losing muscle and bone after menopause are poorly served, and the meta-analysis identifies exactly the subgroup where this class might help: those with muscle loss or refractory bone pain. It also says, in the same breath, that this needs close clinical and laboratory monitoring and larger modern trials. Both halves belong to anyone considering it.
The harms of this class are well characterised and are not exotic. Suppression of the body's own testosterone production through negative feedback, with reduced sperm production that is usually but not always reversible. Adverse lipid changes, typically a fall in HDL cholesterol and a rise in LDL, which is more pronounced with oral 17-alpha-alkylated compounds. Liver strain, again concentrated in the oral alkylated compounds, which is the specific reason those exist as a separate risk category. Raised haematocrit. In women, virilising effects including voice deepening and hair growth that are partly irreversible, which is why dosing in women is a different problem rather than a smaller version of the same one. Cardiac effects at supraphysiological doses are documented and are not the same question as replacement-dose testosterone, which has its own large safety trial.
The evidence, charted
Fig. 1 · evidence composition
3of 4 citations (75%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 1999 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Approved
Approved in 3 of 4, prescription route in 0, not approved in 1. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human1999
Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial
A randomised controlled trial in dialysis patients, published in JAMA, reporting anabolic effects. One of the few randomised trials of an anabolic steroid in a major general medical journal, and the basis of the drug's renal indication.
JAMA - Review2025
Nandrolone decanoate for postmenopausal osteoporosis: a systematic review and meta-analysis of randomized trials
Pooled randomised evidence in postmenopausal osteoporosis. The authors conclude it is a potential adjuvant option for selected postmenopausal women, particularly where muscle loss or refractory bone pain is present, provided treatment occurs under close clinical and laboratory monitoring, and that larger contemporary randomised trials are needed to define its role in modern osteoporosis management.
Cureus - Human2022
Nandrolone decanoate safely combats catabolism in burned patients: a new potential indication after recall
A randomised controlled trial in burned patients. Notable for its framing: the authors present a new potential indication for a drug that had already been recalled, which is an unusual and honest position for a paper to take.
Burns - Human2007
Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study
A randomised phase 2 dose-finding study in chronic kidney disease, which is the kind of dosing work most compounds in this class never received.
Nephron Clinical Practice
Frequently asked questions
Why does a withdrawn drug have good trial evidence?
Because withdrawal is a regulatory and commercial event, not a scientific verdict. Nandrolone has randomised trials in dialysis, chronic kidney disease and burns, and pooled randomised evidence in postmenopausal osteoporosis. Drugs leave markets when alternatives arrive, when indications change, or when sales do not justify the paperwork.
Could it help postmenopausal bone loss?
A 2025 meta-analysis of randomised trials concluded it is a potential adjuvant option for selected postmenopausal women, particularly where there is muscle loss or refractory bone pain, under close clinical and laboratory monitoring. The same authors call for larger contemporary trials to define its role, and modern osteoporosis treatment has options that did not exist when most of this evidence was generated.
Does it really cause sexual dysfunction?
It is a recognised effect and it surprises people, because the drug is an anabolic steroid. The likely reasons are that it aromatises poorly, so it supplies little oestradiol, which has a real role in male libido, and that it reduces to a weaker rather than a stronger androgen in tissue. Meanwhile it suppresses your own testosterone as effectively as anything else in the class.
How long does it stay detectable?
Far longer than its half-life suggests. Metabolites persist for months, which matters for anyone subject to drug testing in sport or employment, and is the specific reason this compound has an outsized presence in doping cases.